Regulation of MDR1 gene expression: Emerging concepts

Drug Resistance Updates

Volumn 3, Issue 2, 2000, Pages 99-108

  Kantharidis, Phillip ^a   El Osta, Sam ^a   De Silva, Michelle ^b   Lee, Grace ^a   Hu, Xiu F ^a   Zalcberg, John ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CHLORAMBUCIL; CISPLATIN; COLCHICINE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; HYDROXYUREA; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; VINBLASTINE;

CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SWITCHING; GENETIC RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; ONTOGENY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTION REGULATION;

EID: 0034176469     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0121     Document Type: Article

References (67)

1. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci. 95:1998;7024-7029.
2. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 93:1999;1075-1085.
3. Sikic B. Pharmacologic approaches to reversing multidrug resistance. Sem Hematol. 34:1997;40-47.
4. Harrison DJ. Mechanisms of drug resitance in tumours. J Pathol. 175:1995;7-12.
5. Dalton W.S. Mechanisms of drug resistance in hematological malignancies. Seminars Hematol. 34:1997;3-8.
6. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Europe J Cancer. 32A:1996;912-920.
7. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:1993;385-427.
8. Chen G, Jaffrezou J-P, Fleming WH, Duran GE, Sikic BI. Prevalence of multidrug resistance related to activation of the MDR1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res. 54:1994;4980-4987.
9. Chin K-V, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science. 255:1992;459-462.
10. Zhou G., Kuo M.T. Wild-type p53-mediated induction of rat MDR1 b expression by the anticancer drug daunorubicin. J Biol Chem. 273:1998;15387-15394.
11. De Angelis P., Stokke T., Smedshammer L. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer. 72:1995;307-311.
12. de Kant E, Heide I, Thiede C, Herrmann R, Rochlitz CF. MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol. 122:1996;671-675.
13. Rafki N., Liautaud-Roger F., Devy L., Trentesaux C., Dufer J. P53 expression in human multidrug-resistant CEM lymphoblasts. Leukemia Res. 21:1997;147-152.
14. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet. 29:1995;607-649.
15. Glazer RI, Rohlff C. Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Res Treatm. 31:1994;263-271.
16. Sundseth R., MacDonald G., Ting J., King C. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Molec Pharmacol. 51:1997;963-971.
17. Rohlff C., Glazer R.I. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol. 12:1998;383-386.
18. Cornwell MM, Smith DE. A signal transduction pathway for activation of the MDR1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem. 268:1993;15347-15350.
19. Bouffard DY, Ohkawa T, Kijima H et al. Oligonucleotide modulation of multidrug resistance. Europ J Cancer. 32:1996;1010-1018.
20. Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci. 91:1994;11123-11127.
21. Ohga T., Koike K., Ono M. et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 56:1996;4224-4228.
22. Ohga T., Uchiumi T., Makino Y et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem. 273:1998;5997-6000.
23. Cornwell MM, Smith DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem. 268:1993;19505-19511.
24. McCoy C, Smith DE, Cornwell MM. 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by ERG1. Molec Cell Biol. 15:1995;6100-6108.
25. Combates NJ, Rzepka RW, Chen Y-NP, Cochen D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem. 269:1994;29715-29719.
26. Zhou G., Kuo M. T. NF-kB-mediated induction of MDR1 b expression by insulin in rat hepatoma cells. J Biol Chem. 272:1997;15174-15183.
27. Rohlff C, Glazer RI. Regulation of multidrug resistance through the cAMP and EGF signalling pathways. 1995, 7, 431, 443.
28. Fine RL, Chambers TC, Sachs CW. P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells. 14:1996;47-55.
29. Hu YP, Robert J. Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance. J Cancer Res Clin Oncol. 123:1997;201-210.
30. Mickley LA, Bates S, Richert ND et al. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiation agents. J Biol Chem. 264:1989;18031-18040.
31. Jin S., Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase in mediated by NF-Y. Molec Cell Biol. 18:1998;4377-4384.
32. Morrow C. S., Nakagawa M., Goldsmith M. E., Madden M. J., Cowan K. H. Reversible transcriptional activation of MDR1 by sodium butyrate treatment of human colon cancer cells. J Biol Chem. 269:1994;10739-10746.
33. Kantharidis P., El-Osta A., deSilva M et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res. 3:1997;2025-2032.
34. Kusaba H., Nakayama M., Harada T et al. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1 /PGY1 gene in mouse L cells by YAC mediated transfer. Somat Cell Mol Genet. 23:1997;259-274.
35. Desiderato L., Davey MW, Piper AA. Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet. 23:1997;391-400.
36. Nakayama M., Wada M., Harada T et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 92:1998;4296-4307.
37. Chin K-V., Tanaka S., Darlington G., Pastan I., Gottesman M.M. Heat shock and arsenite increase the expression of the of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem. 265:1990;221-226.
38. Miyazaki M., Kohno K., Uciumi T et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem Biophys Res Comm. 187:1992;677-684.
39. Kioka N., Yamano Y., Komano T., Ueda K. Heat shock responsive elements in the induction of the multidrug resistance gene (MDR1). FEBS Lett. 301:1992;37-40.
40. Tanimura H., Kohno K., Sata S et al. The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Res Comm. 183:1992;917-924.
41. Chin K-V., Chauhan S. S., Pastan I., Gottesman M. M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Diff. 1:1990;361-365.
42. Chaudhary P. M., Roninson I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 85:1993;632-639.
43. Hu X. F., Slater A., Rischin D., Kantharidis P., Parkin J. D., Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukemia call line. Br J Cancer. 79:1999;831-837.
44. Hu F., Slater A., Kantharidis P et al. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood. 93:1999;4086-4095.
45. Abolhoda A., Wilson A. E., Ross H et al. Rapid activation of the MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 5:1999;3352-3356.
46. Areci R. J., Baas F., Raponi R et al. Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus. Molec Reprod Dev. 25:1990;101-109.
47. Mallick, S. Horwitz, S. B. Transcriptional regulation of the murine multidrug resistance gene mdr1b by progesterone occurs via an indirect mechanism. 1997, 16, 807, 818.
48. Bargou R. C., Jurchott K., Wagener C et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 3:1997;447-450.
49. Oda Y., Sakamoto A., Shinohara N et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 4:1998;2273-2277.
50. Doetzlhofer A., Rotheneder H., Lagger G. et al. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol. 19:1999;5504-5511.
51. Das K. C., White C. W. Activation of NF-kB by antineoplastic agents. J Biol Chem. 272:1997;14914-14920.
52. Yang J. M., Sullivan G. F., Hiat W. N. Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol. 53:1997;1597-1604.
53. Osborn M. T., Chambers T. C. Role of the stress-activated/c-jun NH2 terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem. 271:1996;30950-30955.
54. de Silva M., Kantharidis P., Wall DM et al. Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids. Br J Cancer. 73:1996;169-174.
55. Mickley L. A., Spengler B. A., Knutsen T. A., Biedler J. L., and Fojo T. Gene rearrangement: A novel mechanism for MDR-1 gene activation. J Clin Invest. 99:1997;1947-1957.
56. Stein U., Walther W., Wunderlich V. Point mutations in the MDR1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer. 30A:1994;1541-1545.
57. Ura K., Kurumizaka H., Dimitrov S., Almouzni G., Wolffe A. P. Histone acetylation: influence on transcription, nucleosome mobility and positioning and linker histone-dependent transcriptional repression. EMBO J. 16:1997;2096-2107.
58. Frommel T. O., Coon J. S., Tsuruo T., Roninson I. B. Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines. Int J Cancer. 55:1993;297-302.
59. Li Q., Herrler M., Landsberger N et al. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation responsive transcription from the xenopus hsp70 promoter in vivo. EMBO J. 17:1998;6300-6315.
60. Tanaka H., Ohshima N., Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug western. Molec Pharmacol. 55:1999;356-363.
61. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J. 17:1998;4905-4908.
62. Buschhausen G., Wittig B., Graessmann M., Graessmann A. Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 84:1987;1177-1181.
63. Boyers J., Bird A. DNA methylation inhibits transcription indirectly via methyl-CpG protein. Cell. 64:1991;1123-1134.
64. Kass S. U., Pruss D., Wolffe A. P. How does DNA methylation repress transcription? Trends Genet. 13:1997;444-449.
65. Fryxell K. B., McGee S. B., Simoneaux D. K., Willman C. L., Cornwell M. M. Methylation of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. Leukemia. 13:1997;910-917.
66. Kass S. U., Pruss D., Wolffe A. P. How does DNA methylation repress transcription? Trends Genet. 13:1997;444-449.
67. Nan X., Campoy J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 88:1997;471-481.